Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: Case report and review

Dermatology

Volumn 225, Issue 1, 2012, Pages 14-17

  Puig, Lluís ^a   Morales Múnera, Caridad E ^a   López Ferrer, Anna ^a   Geli, Carme ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Paradoxical psoriasis; Psoriatic arthritis; TNF antagonist; Ustekinumab

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CYCLOSPORIN A; ETANERCEPT; ETRETIN; ISONIAZID; METFORMIN; METHOTREXATE; METHOXSALEN; NAPROXEN; PREDNISONE; USTEKINUMAB;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASYMPTOMATIC DISEASE; CASE REPORT; CHEMOPROPHYLAXIS; DACTYLITIS; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; FOLLICULITIS; HAND PAIN; HEPATITIS C; HUMAN; HYPERKERATOSIS; INTERPHALANGEAL JOINT; KNEE PAIN; LIVER TOXICITY; METACARPOPHALANGEAL JOINT; MORNING STIFFNESS; NAIL DYSTROPHY; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULE; PUSTULOSIS PALMOPLANTARIS; PUVA; REVIEW; SCALP; TIETZE SYNDROME; TUBERCULIN TEST; VISUAL ANALOG SCALE; WALKING DIFFICULTY;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, PSORIATIC; DRUG ERUPTIONS; FEMALE; HUMANS; MIDDLE AGED; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867743264     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000339864     Document Type: Review

References (36)

1. De Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al: Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007; 143: 223-231. (Pubitemid 46294587)
2. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G: Tumor necrosis factoralpha inhibitor-induced psoriasis or psoriasiform exanthemata: First 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9: 1-14.
3. Wendling D, Balblanc JC, Briançon D, Brousse A, Lohse A, Deprez P, et al: Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy. Joint Bone Spine 2008; 75: 315-318.
4. Collamer AN, Guerrero KT, Henning JS, Battafarano DF: Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action. Arthritis Rheum 2008; 59: 996-1001. (Pubitemid 351990997)
5. Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al; British Society for Rheumatology Biologics Register Control Centre Consortium: Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68: 209-215.
6. Collamer AN, Battafarano DF: Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40: 233-240.
7. El Shabrawi-Caelen L, La Placa M, Vincenzi C, Haidn T, Muellegger R, Tosti A: Adalimumab-induced psoriasis of the scalp with diffuse alopecia: A severe potentially irreversible cutaneous side effect of TNF-alpha blockers. Inflamm Bowel Dis 2010; 16: 182- 183.
8. Viguier M, Richette P, Bachelez H, Wendling D, Aubin F: Paradoxical cutaneous manifestations during anti-TNF-alpha therapy. Ann Dermatol Vénéréol 2010; 137: 64-71.
9. Borrás-Blasco J, Gracia-Perez A, Nuñez-Cornejo C, Rosique-Robles JD, Mateu-Puchades A, Casterá MD, et al: Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab. J Clin Pharm Ther 2008; 33: 321-325. (Pubitemid 351629757)
10. Rallis E, Korfitis C, Stavropoulou E, Papaconstantis M: Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: A 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction? J Dermatolog Treat 2010; 21: 3-5.
11. Mourão AF, Rustin M, Isenberg D: Exacerbation of psoriatic skin lesions in patients with psoriatic arthritis receiving anti-tumour necrosis factor-alpha therapy: Description of 3 cases and review of the literature. Clin Exp Rheumatol 2010; 28: 408-410.
12. Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR: Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: A new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011; 34: 1318-1327.
13. Sari I, Akar S, Birlik M, Sis B, Onen F, Akkoc N: Anti-tumor necrosis factor-alpha-induced psoriasis. J Rheumatol 2006;33: 1411- 1414.
14. Chu DH, Van Voorhees AS, Rosenbach M: Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: A report of 2 cases. Arch Dermatol 2011; 147: 1228-1230.
15. Gerdes S, Franke J, Domm S, Mrowietz U: Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol 2010; 163: 1116-1118.
16. De Unamuno-Bustos B, Ballester-Sánchez R, Oliver-Martínez V, Alegre de Miquel V: Ustekinumab for the treatment of palmarplantar pustulosis. Actas Dermosifiliogr 2011; 102: 833-835.
17. Safa G, Martin A, Darrieux L: Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis. J Clin Rheumatol 2011; 17: 385-386.
18. Bulai Livideanu C, Lahfa M, Mazereeuw-Hautier J, Paul C: Efficacy of ustekinumab in palmoplantar psoriasis. Dermatology 2010; 221: 321-323.
19. Nuño-González A, Gómez de la Fuente E, Vicente-Martín FJ, López-Estebaranz JL: Good response of hyperkeratotic palmoplantar psoriasis to ustekinumab. Actas Dermosifiliogr 2012; 103: 169-170.
20. Au SC, Goldminz AM, Kim N, Dumont N, Michelon M, Volf E, et al: Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis. J Dermatolog Treat 2012, E-pub ahead of print.
21. Rallis E, Kintzoglou S, Verros C: Ustekinumab for rapid treatment of nail psoriasis. Arch Dermatol 2010; 146: 1315-1316.
22. Rigopoulos D, Gregoriou S, Makris M, Ioannides D: Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: An open prospective unblinded study. Dermatology 2011; 223: 325-329.
23. Patsatsi A, Kyriakou A, Sotiriadis D: Ustekinumab in nail psoriasis: An open-label, uncontrolled, nonrandomized study. J Dermatolog Treat 2011, E-pub ahead of print. 24 Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Japanese Ustekinumab Study Group: Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial. J Dermatol 2012; 39: 242-252.
24. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, et al: Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633-640.
25. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, et al; Ustekinumab Crohn's Disease Study Group: A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135: 1130- 1141.
26. Sansó Sureda A, Rocamora Durán V, Sapiña Camaró A, Royo Escosa V, Bosque López MJ: Ustekinumab in a patient with Crohn's disease and anti-TNF-induced psoriasis. Gastroenterol Hepatol 2011; 34: 546-550.
27. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J: Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005; 102: 3372-3377. (Pubitemid 40328052)
28. Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T, Taïeb A: Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 2009; 161: 1081- 1088.
29. Michaëlsson G, Kajermo U, Michaëlsson A, Hagforsen E: Infliximab can precipitate as well as worsen palmoplantar pustulosis: Possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? Br J Dermatol 2005; 153: 1243-1244. (Pubitemid 41779595)
30. Borchers AT, Leibushor N, Cheema GS, Naguwa SM, Gershwin ME: Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. J Autoimmun 2011; 37: 273-288.
31. Collamer AN, Battafarano DF: Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40: 233-240.
32. Teraki Y, Tanaka S, Hitomi K, Izaki S: A case of generalized psoriasiform and pustular eruption induced by infliximab: Evidence for skin-homing Th17 in the pathogenesis. Br J Dermatol 2010; 163: 1347-1351.
33. Reddy M, Torres G, McCormick T, Marano C, Cooper K, Yeilding N, et al: Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters. J Dermatol 2010; 37: 413-425.
34. Daudén E, Santiago-et-Sánchez-Mateos D, Sotomayor-López E, García-Díez A: Ustekinumab: Effective in a patient with severe recalcitrant generalized postular psoriasis. Br J Dermatol 2010; 163: 1346-1347.
35. Gregoriou S, Kazakos C, Christofidou E, Kontochristopoulos G, Vakis G, Rigopoulos D: Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis. Eur J Dermatol 2011; 21: 104-105.
36. Wenk KS, Claros JM, Ehrlich A: Flare of pustular psoriasis after initiating ustekinumab therapy. J Dermatolog Treat 2012; 23: 212- 214.